July 2026
M	T	W	T	F	S	S
	1	2	3	4	5
6	7	8	9	10	11	12
13	14	15	16	17	18	19
20	21	22	23	24	25	26
27	28	29	30	31

Ney Carter Borges: Triple Low-Dose Antihypertensive Therapy After Intracerebral Hemorrhage – A Pragmatic and Effective Strategy

Ney Carter Borges/LinkedIn

Apr 28, 2026, 01:17

Ney Carter Borges: Triple Low-Dose Antihypertensive Therapy After Intracerebral Hemorrhage – A Pragmatic and Effective Strategy

Ney Carter Borges, Member Cardiologist of Global Physician Association at Cleveland Clinic Florida, shared a post on LinkedIn:

“Triple Low-Dose Antihypertensive Therapy After Intracerebral Hemorrhage: A Pragmatic and Effective Strategy

This multicenter, randomized, double-blind, placebo-controlled trial (TRIDENT) evaluated whether a fixed-dose combination of three low-dose antihypertensive agents could improve outcomes in patients with prior intracerebral hemorrhage (ICH). The study enrolled 1,670 patients with baseline systolic blood pressure between 130–160 mmHg, randomized to receive either a once-daily triple pill (telmisartan 20 mg, amlodipine 2.5 mg, indapamide 1.25 mg) or placebo, in addition to standard care.

Over a median follow-up of 2.5 years, the intervention demonstrated a clinically meaningful reduction in recurrent stroke.

The primary endpoint occurred in 4.6% of the triple-pill group versus 7.4% in the placebo group (hazard ratio [HR] 0.61; 95% CI 0.41–0.92; P=0.02), corresponding to a relative risk reduction of approximately 39%. This benefit was primarily driven by a substantial decrease in recurrent intracerebral hemorrhage (HR 0.40).

Importantly, the triple therapy achieved superior blood pressure control, with a mean systolic blood pressure of 127 mmHg vs. 138 mmHg in the placebo group, and significantly higher rates of target BP attainment (<130 mmHg) at 6 months (49.9% vs. 26.4%; OR 3.15; P<0.001).

In addition to stroke prevention, the intervention reduced major cardiovascular events (6.6% vs. 9.8%; HR 0.67; P:0.04), although no statistically significant reduction in cardiovascular mortality was observed.

Safety outcomes were broadly comparable between groups, though treatment discontinuation was more frequent in the triple-pill arm (13.6% vs. 6.0%), largely driven by increases in serum creatinine.

From a clinical perspective, the findings support a simplified, fixed-dose combination strategy to enhance adherence and intensify blood pressure control—two critical gaps in post-ICH management. The estimated number needed to treat (NNT) of ~35 underscores meaningful real-world applicability.

In summary, this study provides robust evidence that early initiation of low-dose combination antihypertensive therapy in a single pill significantly reduces recurrent stroke and improves blood pressure control after intracerebral hemorrhage, reinforcing aggressive BP management as the cornerstone of secondary prevention in this high-risk population.”

Ney Carter Borges: Triple Low-Dose Antihypertensive Therapy After Intracerebral Hemorrhage - A Pragmatic and Effective Strategy